Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 24 Mar 2016 Primary end points has been modified.
- 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Feb 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.